Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Lonza Group AG is a global company specializing in pharmaceutical, biotech, and nutrition sectors, headquartered in Basel, Switzerland. It provides integrated solutions for the creation of new drugs, ranging from active pharmaceutical ingredients (APIs) and drug formulation to drug delivery systems. The company serves a diverse clientele including pharmaceutical and biotech companies, offering contract development and manufacturing organization (CDMO) services. With operations in multiple countries, Lonza is strategically positioned to cater to global healthcare needs. Known for its extensive capabilities in cell and gene therapy, the organization leverages advanced technology platforms to support complex biopharmaceutical developments, enhancing its competitive edge in the industry.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
Lonza Group AGAbbVie
Last price
€691.20$285.64
Currency
EUR
USD
€48B$504B
-80.57
-€1.71$3.54
0.810.28
€5.47$6.83
0.40%2.43%
Sector
HealthHealth
Employees
20,14157,000
Ticker
€LONN$ABBV
Primary listing
XGATNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €LONN or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.